---
title: "BUZZ-Virbac shares rise on strong Q1 revenue growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283107227.md"
datetime: "2026-04-17T07:45:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283107227.md)
  - [en](https://longbridge.com/en/news/283107227.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283107227.md)
---

# BUZZ-Virbac shares rise on strong Q1 revenue growth

Shares in Virbac (VIRB.PA) jump 3% after the company reported a strong revenue growth in Q1 driven by strategic “supercharge” platforms, and maintained 2026 guidance

The French animal health company published Q1 revenue at 384 million euros ($452.31 million), up 7.7% yoy at constant exchange rate and scope

“Growth is largely driven by the strategic “Supercharge” platforms, which group together the highest value-added franchises of the group (therapeutic nutrition, reproduction, dental, mobility, otology, endocrinology — strengthened by Thyronorm — and ruminants), says TP ICAP Midcap

The broker adds these platforms are growing by around +15% at constant FX and constitute the main structural engine of the organic growth and value-creation trajectory for the group

Jefferies also flags North America leads regional growth at 20.7%, boosted by momentum in mobility, dental and ear product categories as well as a strong ramp-up of the Thyronorm acquisition

It notes that foreign exchange remains a material headwind, weighing approximately 5.5% on reported growth in the quarter

Management reiterates its full-year 2026 guidance, saying the strong first-quarter performance “continued to give confidence” in its annual targets

Including today’s gains, the stock is up 4.2% year-to-date ($1 = 0.8490 euros)

### Related Stocks

- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [TCAP.UK](https://longbridge.com/en/quote/TCAP.UK.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Billionaire Investor Takes New Stake In Thermo Fisher Scientific](https://longbridge.com/en/news/284771871.md)
- [Boston Scientific Lowers FY26 Guidance](https://longbridge.com/en/news/283651269.md)
- [BioMerieux Q1 Sales Down 3.9% On Organic Basis; Revises 2026 Guidance](https://longbridge.com/en/news/283778021.md)
- [Hemogenyx Pharmaceuticals publishes 2025 annual report](https://longbridge.com/en/news/284800462.md)
- [Align Technology beats Q1 revenue and profit estimates, maintains FY revenue growth forecast](https://longbridge.com/en/news/284636757.md)